Emcure Pharmaceuticals Intrinsic Value
Emcure Pharmaceuticals (EMCURE) median intrinsic value is ₹794.13 from 9 valuation models (range ₹489–₹1131), vs current price ₹1638.00 — -51.5% downside (Trading Above Calculated Value), margin of safety -100.0%. For current market price and key ratios, visit EMCURE stock overview.
EMCURE Valuation Methods Summary — DCF, Graham Number & P/E
Emcure Pharmaceuticals intrinsic value across 9 models vs current price ₹1638.00 — upside/downside and value range per method. Browse EMCURE balance sheet details for revenue, profit, balance sheet and cash flow data.
| Method | Type | Intrinsic Value | Range | Upside/Downside | Details |
|---|---|---|---|---|---|
| P/E Based Valuation | earnings | ₹1130.80 | ₹904.64 - ₹1356.96 | -31.0% | EPS: ₹51.40, Sector P/E: 22x |
| Book Value Method | asset | ₹488.63 | ₹439.77 - ₹537.49 | -70.2% | Book Value/Share: ₹244.32, P/B: 2.0x |
| Revenue Multiple Method | revenue | ₹957.05 | ₹861.35 - ₹1052.76 | -41.6% | Revenue/Share: ₹478.53, P/S: 2.0x |
| EBITDA Multiple Method | earnings | ₹1008.42 | ₹907.58 - ₹1109.26 | -38.4% | EBITDA: ₹1916.00Cr, EV/EBITDA: 10x |
| Simple DCF (5Y) | dcf | ₹655.20 | ₹524.16 - ₹786.24 | -60.0% | CF Growth: 4.9%, Discount: 15% |
| PEG Ratio Method | growth | ₹491.40 | ₹442.26 - ₹540.54 | -70.0% | EPS Growth: 8.0%, Fair P/E: 6.4x |
| Growth Adjusted P/E | growth | ₹794.13 | ₹714.72 - ₹873.54 | -51.5% | Revenue Growth: 6.0%, Adj P/E: 15.5x |
| ROE Based Valuation | profitability | ₹845.47 | ₹760.92 - ₹930.02 | -48.4% | ROE: 21.6%, P/E Multiple: 16x |
| Graham Defensive Method | conservative | ₹491.40 | ₹442.26 - ₹540.54 | -70.0% | EPS: ₹51.40, BVPS: ₹244.32 |
EMCURE Intrinsic Value vs Market Price — All Valuation Models
Emcure Pharmaceuticals fair value range ₹489–₹1131 vs current market price ₹1638.00 across 9 valuation models. Compare with EMCURE fundamental valuation to assess whether the stock is under or overvalued.
EMCURE Intrinsic Value Analysis — Undervalued or Overvalued?
Emcure Pharmaceuticals median intrinsic value ₹794.13, current price ₹1638.00 — Trading Above Calculated Value by 51.5%, margin of safety -100.0%.
What is the intrinsic value of EMCURE?
Based on our comprehensive analysis using 9 different valuation methods, the estimated intrinsic value of Emcure Pharmaceuticals (EMCURE) is ₹794.13 (median value). With the current market price of ₹1638.00, this represents a -51.5% variance from our estimated fair value.
The valuation range spans from ₹488.63 to ₹1130.80, indicating ₹488.63 - ₹1130.80.
Is EMCURE undervalued or overvalued?
Based on our multi-method analysis, Emcure Pharmaceuticals (EMCURE) appears to be trading above calculated value by approximately 51.5%.
EMCURE Financial Health — Key Ratios vs Industry Benchmarks
Emcure Pharmaceuticals financial ratios — ROE, debt-to-equity, profit margins and liquidity vs industry benchmarks and their impact on intrinsic value.
| Financial Metric | Current Value | Industry Benchmark | Assessment | Impact on Valuation |
|---|---|---|---|---|
| Current Ratio | 4.94 | Industry Standard: 2.0+ | Above 2.0 | Measures short-term liquidity capacity |
| Return on Equity | 21.6% | Industry Standard: 15%+ | Above 15% | Measures shareholder return efficiency |
| Operating Margin | 21.0% | Industry Standard: 20%+ | Above 20% | Indicates operational efficiency level |
| Asset Turnover Ratio | 1.10x | Industry Standard: 1.0x+ | Above 1.0x | Measures asset utilization efficiency |
EMCURE Cash Flow Quality — Operating & Free Cash Flow
Emcure Pharmaceuticals operating cash flow, free cash flow, quality rating and sustainability score by period — key inputs to DCF intrinsic value calculation.
| Period | Operating Cash Flow | Free Cash Flow | Cash Flow Quality | Sustainability Score |
|---|---|---|---|---|
| March 2025 | ₹852 Cr | ₹804 Cr | Positive Free Cash Flow | 8/10 |
| March 2024 | ₹1,097 Cr | ₹740 Cr | Positive Free Cash Flow | 8/10 |
| March 2023 | ₹747 Cr | ₹513 Cr | Positive Free Cash Flow | 8/10 |
| March 2022 | ₹768 Cr | ₹481 Cr | Positive Free Cash Flow | 8/10 |
| March 2021 | ₹704 Cr | ₹576 Cr | Positive Free Cash Flow | 8/10 |